logo
  

Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity

Biogen Inc. (BIIB) said that the Phase 3 EVOLVE-MS-2 study demonstrated improved patient-assessed gastrointestinal or GI tolerability of Vumerity, a new FDA-approved treatment for relapsing forms of multiple sclerosis or MS, compared to Tecfidera.
Results for the primary endpoint show patients treated with Vumerity self-reported 46 percent fewer days with intensity scores of =2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), compared to Tecfidera.

The EVOLVE-MS-2 results also indicate that compared to TECFIDERA, VUMERITY-treated patients had lower discontinuations due to GI adverse events (AEs) (0.8 percent vs. 4.8 percent).

VUMERITY is now available in the U.S. for relapsing forms of MS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford Motor Co. on Monday issued a recall for a total of 19,626 2021 F-Series Super Duty vehicles with dual rear wheels in North America. These include 17,616 vehicles in the U.S. and federal territories; 1,779 in Canada; and 231 in Mexico. The affected vehicles are equipped with front-wheel hub extenders... Royal Philips has recalled specific sleep and respiratory care devices due to the potential health risks related to the polyester-based polyurethane or PE-PUR sound abatement foam component. The affected products include Bi-Level Positive Airway Pressure or Bi-Level PAP, Continuous Positive Airway Pressure or CPAP, and mechanical ventilator devices. Freshpet Inc. is recalling a single lot of Freshpet Select Small Dog Bite Size Beef & Egg Recipe Dog Food citing the potential contamination with Salmonella, a bacterium, the U.S. Food and Drug Administration said. The product comes in 1 LB bags, with UPC code of 627975012939, lot code of 1421FBP0101 and sell by date of 10/30/2021.
Follow RTT